Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors and executives interviewed by BioPharma Dive at the J.P. Morgan Healthcare ...

JPMorgan Chase posted strong Q4 results, with EPS up 58% y/y and IB revenues up 46% y/y, beating analyst estimates. Learn ...

According to the World Health Organization (WHO), multidrug-resistant pathogens caused over 1.27 million deaths worldwide in ...

With incoming president Donald Trump threatening a trade war with China, experts told BioSpace that the new administration ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

It's 2025, and the Apple Card saga is still unfolding. Now, a new player is joining the mix, while Goldman Sachs seems eager to bow out.

The price of Litecoin soared by double-digits in the past 24 hours to reach a four-week high of $118, as optimism brews ...

JPMorgan Chase today announced new responsibilities for several senior executives as it continues to build on its leadership positions across global financial services. Daniel Pinto, President and ...

NeoGenomics Inc. shared a strong financial outlook for 2025 and beyond. The Fort Myers-based cancer testing and research lab ...

Payments fees grow by double digits for the fourth consecutive quarter, helping drive payments revenue to a record $18.1bn ...

With positive data in hand from its phase IIb trial testing immunotherapy candidate OST-HER2 in osteosarcoma, OS Therapies ...